Sudocrem boss: new skin drug will net €1.5bn - Raglan Capital

Home
About Us
Selected Transactions
Raglan IPO Projects
- Raglan Pharmaceutical & Life Science Projects
- Raglan Natural Resources
News
Contact us

Search

Sudocrem boss: new skin drug will net €1.5bn

Home
Amryt Pharma
Sudocrem boss: new skin drug will net €1.5bn

Recent News

Open Orphan signs €4.4m contract with global company
Open Orphan wins €4m contract to conduct trial for new RSV treatment
Open Orphan deal to generate ‘significant revenue’ for Venn Life Sciences
Open Orphan signs deal to carry out Covid-19 vaccine trial
Open Orphan agrees contract for Covid-19 vaccine trial
Open Orphan wins contact for Covid-19 vaccine trial

10 April 2016

Sudocrem boss: new skin drug will net €1.5bn 10 April 2016 online article

Prev
Next

Join us for our newsletters

Raglan Capital
18 Fitzwilliam Place, Dublin 2.
T: +353 1 6440007
E: info@raglancapital.ie

Contact us
Careers
Privacy Policy
Cookie policy (EU)

Join us for our newsletters

Raglan Capital
18 Fitzwilliam Place, Dublin 2.
T: +353 1 6440007
E: info@raglancapital.ie

Contact us
Careers
Privacy Policy
Cookie policy (EU)

© 2020 Raglan Capital. All rights reserved

Privacy Preference Center

Privacy Preferences